New Drug Expands Limited Treatment Arsenal for for Colorectal Cancer

University of Pennsylvania Cancer Center
Last Modified: May 18, 1998

Share article


Colorectal cancer is one of the most common malignancies, with over 131,000 new cases diagnosed in the U.S. each year. 5FU has been used as the primary treatment for colon cancer for decades, with few effective new drugs to complement this therapy. Patients who do not respond to the standard chemotherapy treatment for metastatic colorectal cancer have few treatment options beyond supportive care as the tumor progresses.

In this phase III multicenter randomized trial, researchers report that a new agent, CPT-11, increased survival time and quality of life compared to supportive care alone and should be offered as a standard treatment in patients resistant to treatment with 5-Fluorouracil (5FU). This 279 patient study showed that patients receiving CPT-11 lived 2.6 times longer than patients receiving only su`pportive care, and that quality of life measurements were higher in the CPT-11 patients.


News
New Target Eyed for Colorectal Cancer Treatment

Dec 21, 2014 - Drugs targeting the pseudo-kinase ERBB3 -- which is closely related to the epidermal growth factor receptor that has been investigated as a target for treatment of colorectal cancer -- might be more effective in treating colorectal cancer, according to research published online Aug. 17 in the Journal of Clinical Investigation.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More